BUDWIG CENTER ECT - Electro Cancer Therapy                                        By far, the most exciting development in...
and/or degraded by the immune system’s scavenger cells (phagocytes). During atreatment, an electrical field is created and...
At the same time, tumour antigens are released and increasingly recognised by theattracted immune cells. A renewed creatio...
•   Melanomas and basal-cell carcinomas   •   Skin metastases   •   Lymph node metastases   •   Liver metastases   •   Myc...
6.1-8.0 cam, 102 cases 8.1-10.0 cm and 49 cases >10.1 cm. In this group, none was at 1stage, 103 cases were at II stage, 8...
TNM classification of 386 cases included 11103 cases (26.7 %)‚ lIla 89 cases (23.1 %)‚IlIb 122 cases (31.6%) and IV 72 cas...
Our experimental results and clinical experiences showed that the radius of tumourtissue killed area around each electrode...
between 4-6 cm were treated by only two electrodes, one anode and one cathode.Electric quantity used was totally 200-300 c...
later, the tumour disappeared totally. Hi lived well and resumed his work afterfollowing up for 5 years. (Fig. 3)Mr. Cheng...
carcinoma                        203               65            32.0             104         51.3             23       11...
www.BudwigCenter.com 11
Upcoming SlideShare
Loading in …5
×

Electro Cancer Therapy - ECT

1,528
-1

Published on

This document provides information on the Electro Cancer Therapy as used by the Budwig Center in Spain. We have so far experienced some excellent results using this particular treatment with various forms of cancer including prostate, cervical, lung, breast and skin cancers. Visit us at http://www.budwigcenter.com for more information.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,528
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Electro Cancer Therapy - ECT

  1. 1. BUDWIG CENTER ECT - Electro Cancer Therapy By far, the most exciting development in cancer treatment is ECT. We continue to see outstanding results for our patients who have received ECT at the clinic, and have remained cancer free for several years after the procedure. ECT is highly effective for patients with certain cancers, mainly prostate, cervical, vulva, skin, breast, lung, head and neck, and ECT is even having success with some cancers that are usually more difficult to treat, such as stomach, liver and pancreatic tumours. It is not unusual for a tumour to be reduced by fifty percent, after the first ECT treatment.Many of our patients choose ECT to avoid the unpleasant effects of conventionalcancer treatments that can impact heavily on their lives.Usually just one session of two or three hours the ECT causes the necrosis (death tothe cancer tumor) and no more is needed. ECT is some cases would be a naturaloption to surgeryIt is a highly promising and often successful gentle treatment modality which seems tobe widely applied in China and in some European venues such as Germany, Austria,Holland, Spain, France and Italy. It involves the targeted application of a few milliampsbiological electrical DC current to cancerous growths which often results in thecomplete destruction of malignant tumors. Applied as outpatient treatment, it issuperior to surgical excision both because no residual cancer cells are able to survivethe process and in respect to expenses incurred.How it worksECT starts to work through the metabolic system of the tumour cell and has a positiveinfluence on the immunisation process. After the patient receives a local aesthetic and mildsedative electrical poles (electrodes) which cause low voltage direct current to flow throughthe area are attached in and on the tumorous areas. The electrical resistance of thetumour cells is reduced so that the low voltage current can only focus to cause damageto these but not to the healthy tissue. In this manner, growths are caused to graduallydie off in a sterile state (aseptic bionecrosis), often in a single session with a durationof up to three hours. The cancer tissue is now rejected by the healthy body by degrees www.BudwigCenter.com 1
  2. 2. and/or degraded by the immune system’s scavenger cells (phagocytes). During atreatment, an electrical field is created and loaded particles (ions) are drawn to therespective poles (electrolysis), for example Na+ and H+ to the cathode (negative pole)and Cl- to the anode (positive pole). This results in the creation of an alkalineenvironment around the cathode and an acidic environment around the anode. The Phvalues are in both cases far from the physiological area and have a destructive effecton the tissueHere are some cases of cancer treated at the clinic by Dr. LopezTumor on Arm BEFORE ECT ECT - Facial Tumor Arm totally healed in 30 days ECT - Breast Adenocarcinoma Necrosis of tumor (death) 1 week later Tumor gone [Note: All ECT Therapy sessions are performed by Dr Lopez in a Medical Clinic]3 hours later necrosis and tumorfalls out for natural healing tonow startThe membrane potentials alter when the electrolytic environment in and around thecells is changed. The membrane becomes perforated in the accelerated ion flow anddisturbances in the metabolic functions and intercellular structures take place. The cellbecomes vulnerable to immune cells, because these are no longer electrically repelled. www.BudwigCenter.com 2
  3. 3. At the same time, tumour antigens are released and increasingly recognised by theattracted immune cells. A renewed creation of metastases is effectively counteractedbecause the current is already active during the attachment of the electrodes and anytumour cells which may be released are held in the electrical field. Advantage of theECT electro-tumor therapy (also called Galvano-therapy)Another tremendous advantage that needs to be emphasized is that in the ECT(electro-tumor therapy) the risk of metastasis formation can be practically excluded,since such a preventive measure is counteracted. With surgery there is always the restthat some cancer “seeds” or “threads” remain and the tumor grows back. With ECTthe necrosis (death) effect on the cancer tumor literally causes the entire mass to dieand be expelled naturally by the bodyA tumor, like the rest of our body, is composed of individual cells. This complementarymethod puts the body in a position to defeat the cancer and improve the wellbeing ofthe patient.The name “Electro-Cancer Therapy” in spirit means that not cause the current in andfor the formation of hydrochloric acid, the cure, but also the self through the body isinitiated when it receives the current signal. Thus, the tumor and the immune systemloses its camouflage starts with the defence against malignant tissue, put it simplyactivate the natural healing abilities.How much is an ECT treatment and how long does it take?A current treatment takes between two and three hours and is computer controlled,so that the doctor can precisely control the processes in the body.The following articles while furnishing scientific details will also give an excellentgeneral introduction to the subject: • Types of Tumors Responding to Galvanotherapy • Electrochemical Tumor Therapy (ECT) for Malignancies • Bio-Electric Therapy (BET) For the Elimination of Malignant Tumors • Prof. Dr. Yu-Ling Xin’s Treatment Statistics Concerning ECT (Electro Chemo Therapy) • Important AddendaParticular tumor types respond well to ECT…. • Breast cancers • Mouth and throat cancers • Esophageal and stomach cancers • Lung cancers • Vaginal cancers www.BudwigCenter.com 3
  4. 4. • Melanomas and basal-cell carcinomas • Skin metastases • Lymph node metastases • Liver metastases • Mycosis fungoides • Rectal cancer & anal cancerThe use of ECT for malignant tumor removal has many advantages. Such benefitsconsist of the following:a. The organ involved is preserved with no problematic scarring.b. The electrical needles are applied under local anesthesia without risks.c. None of the side effects which may be connected with general anesthesia arepresent.d. No damage occurs to healthy tissue.e. As a result of lysed tumor components being presented to the immune system forremoval, an additional immune stimulation takes place.From receiving ECT, certain types of cancer patients benefit greatly. Such malignancytypes include: those with small primary tumors of less than 5 cm in diameter. At the Budwig Center we treat every size of tumors even 10 cm, however it would take 4 or 5 sessions in such cases those with solitary metastases, especially in the skin and lymph nodes; those with recurrences in the region of an operation such as a mastectomy scar; those who have inoperable external tumors.Clinical Study done in China with ECTEffectiveness of Electrochemical Therapy in the Treatment ofLung Cancers of Middle and Late Stage in China StudyXin Yu-Ling, Xue Fu-Zhou, Ge Bing-Sheng, Zhao Feng-Rui, Shi Bin, and Zhang Wei(Department of Thoracic Surgery, China-Japan Friendship Hospital,Beijing 100029)ABSTRACTObjective To investigate the effect of electrochernical therapy (ECT) in the treatmentof middle and late stage lung cancers.Materials and Methods 386 cases (287 males and 99 females) with middle and latestage cancers were treated with ECT. The oldest was 78 years old and the youngestwas 25 with an average age of 51 years. Two hundred and three patients had gotsquamous cell carcinoma; 138 Aden carcinoma and 45 undifferentiated cancer.Diameters of the cancer were listed as follows: 153 cases were 4.0-6.0 cm, 82 cases www.BudwigCenter.com 4
  5. 5. 6.1-8.0 cam, 102 cases 8.1-10.0 cm and 49 cases >10.1 cm. In this group, none was at 1stage, 103 cases were at II stage, 89 cases lIla, 122 cases HIb and 72 cases IV. Among386 cases, 152 cases (39.4 %) were with hypertension, heart disease etc. Anode andcathode platinum electrodes were inserted accurately into the tumour mass. Distancebetween two electrodes was 2-2.5 cm. Electrodes were connected to a special ECTinstrument. The current was maintained at 6-8 V and 80-100 mA. 100 coulombs isapplied for treating 1 cm diameter of tumour mass.Results: Short term effectiveness In 386 cases, 99 cases (25.6 %) were CR, 179 cases(46.4 %) PR, 59 cases (15.3 %) NC and 49 cases (12.7 %). Effective rate (CR +PR) was 72% (278 cases). Long term effectiveness One to have year survival rates were 86.3 %‚76.4 %‚ 58.8 %‚ 39.9 % and 29.5 %‚ respectively.Conclusion : ECT is used easily, effective, safe, less traumatic and makes patientsrecover quickly. This is a new and effective method to treat patients with tumours whoare inoperable and cannot receive chemotherapy or radiotherapy.Electrochemical therapy - lung cancerElectrochemical therapy (ECT) is a method to kill tumours by inserting platinumelectrodes into the tumour and connecting electrodes to a direct-current instrument.Free chiorine, oxygen and hydrogen are produced due to electrolysis in the tumourtissue. And there is strong alkalinity and acidity appeared at cathode and anode,respectively. All the effects can destroy tumour cells. As early as 1970‘s, ECT has beenused to treat malignant tumours. In 1983, B. Nordenström (1) published a manuscriptdescribing systematically the resuits of fundamental experiments and clinicaltherapeutic effectiveness of ECT.Since 1987, based on the experiences of B. Nordenström (2), we have madeexperimental study on ECT and applied it to clinical practice (3). By the end of 1994,more than 6600 cases with various kinds of tumours had been. treated with ECT inabout one thousand hospitals in China. The total effective rate (CR + PR) was 60—80 %in different hospitals. At the First International Symposium on ECT of Cancers held inBeijing in 1992, we reported the application of ECT to 2516 cases of various kinds oftumours. The total effective rate was 78.1 % (4).In this paper, ECT of 386 cases of middle and late stage lung cancers from October1987 to February 1989 was reported.Clinical dataOf the 386 cases, 287 cases were male and 99 female. The oldest was 78 years old andyoungest 25; with an average age of 51 years. The diameters of tumours measured onX-ray film were 4-6 cm in 82 cases, 6.1- 8.0 cm 153 cases, 8.1-10.0 cm 102 cases and>10.1 cm 49 cases. There were 151 patients (39.1 %) bearing tumours >8.0 cm.According to pathological examination, 203 cases belonged to squamous cellcarcinoma, 138 Aden carcinoma; and 45 undifferentiated carcinoma. (Table 1) www.BudwigCenter.com 5
  6. 6. TNM classification of 386 cases included 11103 cases (26.7 %)‚ lIla 89 cases (23.1 %)‚IlIb 122 cases (31.6%) and IV 72 cases (18.6 %). The number of cases at middle stage (II+ lIla =192) was about the same as that of late stage cases (Ilib + IV =194). (Table 2)Metastases were more common in cases with lung adenocarcinoma (50.0 %) than thatin squamous cell carcinoma (37.5 %) or undifferentiated carcinoma (12.5 %). Throughlymphatic system, there were metastases to pleura (21 cases), cervical lymph nodes(18 cases) and liver (6 cases); and through blond stream to bone (16 cases) and chestwall (11 cases).In the 386 cases, 39 cases had thoracotomy, 32 cases received radiotherapy (over 4000cGy), 66 cases received chemotherapy three times, and 65 cases received traditionalChinese medicine for 4-6 weeks. All these treatments were of no effect to the patientsbefore they came to have ECT.As for complications of the 386 cases, there were 39 cases accompanied withhypertension and 41 cases with coronary heart disease, 31 with chronic bronchitis andemphysema (lung vital capacity <40 % of normal value) and 41 with diabetes.Therapeutic methodEither of the two types of therapeutic instruments was used: (1) Type BK 91A withadjustable voltage, ampere and electricity quantity buttons and devices for presentingtime and auto-alarm. (2) Type BK 92A with Computer to control the above functions. Inaddition there are expert systems with video picture showing the size of tumour,automatic calculation of the number of electrodes and functions for recording, printingand storing data. Flexible sort or hard platinum electrodes were used according to theconditions of tumour location and constitution. Local, subdural or general anaesthesiawas used according to patients‘ conditions.For those cases without thoracotomy, insertion of electrodes was done under X-ray orCT monitoring. A stylet with insulating tubing outside was inserted first into thetumour, then the stylet was withdrawn out. The electrodes then inserted in throughthe tubing and passing all through the tumour mass. The insulating tubing was, then,used to protected normal tissue against damage by electricity. After insertion of all theelectrodes, the patient was asked to lie on bed calmly.Electrodes were, then, connected to the instrument. Voltage was gradually raised upto the desired voltage and current was raised up accordingly and maintained at 40-60or 80-100 niA. The effect of ECT with lower amperage (40-60 mA) and longer duration(2-2.5 h) is better than that of ECT with higher amperage (100-150 mA) and shorterduration (1-1.5 h). This is because that electrolysis needs a longer time to destroyturnour tissue. 4V and 20 mA are the minimal limit for ECT. Experimental resultsshowed that about 100 coulomb per 1 cm of diameter of tumour tissue is needed forkilling effects. Cicatricial tumours, with less electrolytes in them, need more electricity,while squamous cell carcinomas, with more electrolytes in them, need a lowerquantity of electricity. www.BudwigCenter.com 6
  7. 7. Our experimental results and clinical experiences showed that the radius of tumourtissue killed area around each electrode is about 2 cm. The distance betweenelectrodes, thus, should not exceed 2.5 cm. Based on the size and shape of tumour,the number of electrodes could be determined. Usually, anodes are placed in thecentre and cathodes near the periphery of tumour, with a distance not more than 2 cmto the edge of tumour in order to prevent normal tissue from electricity damage.Complications of ECT The main complication, when happened, was traumaticpneumothorax occurring usually with the central type of lung cancer or lung cancerwith chronic bronchitis and emphysema. The incidence was 14.8 % (57/3 86). In the 57cases, 25 had their lungs collapsed by more than 1/3, which were treated immediatelywith pleural cavity drainage; 32 had only small area of pneumothorax with nobreathing difficulty, hence, no treatment was given and ECT carried on continuously.As a preventive measure, oxygen breathing and injection of codeine and diazepam tokeep patients in a calm condition could reduce the incidence of pneumothorax.Therapeutic effectiveness The therapeutic effectiveness feil into CR, PR, NC and PDaccording to the standards by WHO in 1978. Short term effectiveness can be seen inTable 3. The total effective rate72.0 %. And effective order of short term effectiveness is squamous cell carcinoma(83.3 % adenocarcinoma (63.8 %) and undifferentiated carcinoma (46.7 %). TNMstaging was closely related to short term effectiveness. (Table 4) The effectivenessdecreased with the increase of stage. That of Stage II was 90.3 %‚ III (66 +79/89 + 122 x100) 68.7 % and IV 55.6 %. There was significant difference between these groups.The total short term effectiveness decreased as die size of tumour increased. (Table 5)Effective rate for tumours with diameter less than 8 cm ‘~vas 83.4 % (71 + 125/82 +153 x 100) and that of tumours with diameter greater than 8 cm was 54.3 % (64 +28/102 + 49 x 100). There was significant difference between these two groups.One to five year survival rates were calculated by Kaplan-Meier‘s method in 1958.There were 53 cases that died within one year. In the remaining 333 cases, 18 werelost after one year. The results were listed in Table 6. One to five year survival rateswere 86.3 %‚ 76.4%, 58.8 %‚ 39.9 % and 29.5 %‚ respectively. Five year survival rate ofcases with squainous cell carcinoma is higher than that of cases with adenocarcinomaand undifferentiated carcinoma. There was significant difference between them. Table7 showed that the survival rates of stages II and IIIa were higher that that offstage IV.While there was no cases of stage IV survived five years. The difference betweensurvival rates of different stages was statistically significant.The survival rate of cases with tumour diameter of 4.0-8.0 cm, 35.7 % (40 + 44/82 +153 x 100) was significantly higher than that of cases with tumour diameter longerthan 8.1 cm, 19.9 % (30/151)Factors affecting effectiveness Number of electrodes and quantity of electricity affectshort term effectiveness. In 1987 to 1988, 40 cases of Jung cancer with diameter www.BudwigCenter.com 7
  8. 8. between 4-6 cm were treated by only two electrodes, one anode and one cathode.Electric quantity used was totally 200-300 coulomb. Clinical effectiveness of this groupshowed that CR accounted for 17.5 % (7/40), PR 32.5 % (13/40) and CR + PR 50.0 %.Animal experiments in 1988 showed that diameter of killing area around eachelectrode was 2.5 cm and electric quantity needed was 100 coulomb per 1 cmdiameter of tumour tissue. Since February 1989, 42 cases of Jung cancer have beentreated by ECT with the above data. The effectiveness has been raised markedly withCR 28.6% (12142), Pr 45.2 % (19/42) and CR+ PR 73.8%. There is significant differencebetween these two groups.Factors affect long term effectiveness are:(1) the stage of tumour; as shown in Table 4;(2) size of tumour, as shown in Table 5; (3) pathological type of tumour, as shown inTable 6; and (4) the recurrence rate of tumour. In the 386 cases, 99 cases accounted asshort term CR. Five years later, 18 cases (18.2 %) died of local recurrence, 21(21.2 %)died of general metastasis, and 60 (60.6 %) survived over 5 years. Of the 179 caseswith PR, 55 cases (30.7 %) died of local recurrence, 70 (39.1 %) died of generalmetastasis and 54 (30.2 %) survived over 5 years.Discussion: An improved method, ECT, was applied for the treatment of 386 cases oflung cancer. The short term and long term effectiveness is comparable with that ofsurgical Operation and better than that of chemo- or radiotherapy. Therapeuticeffectiveness of ECT in treating middle stage Jung cancer with no metastasis is good.72 cases of stage IV lung cancer and remote metastasis have been treated with ECT toeliminate the primary focus. And other therapeutic measures including radio- and/orchemotherapy and traditional Chinese medicines were combined with for the controlof remote metastasis. Patients had less suffering and their live might be prolonged.The other therapeutic measures have also been used in combination with ECT fortreating cases with tumour size greater than 8 cm. Correct insertion of electrodes,enough electric quantity and therapeutic time are important. Lung cancers that werefound to be inoperable during thoracotomy, could be treated with ECT right away.Electrodes, hence, could be inserted wider direct vision. Good effectiveness could beobtained by ECT in treating tumours which are solitary and its size Jess than 8 cm. ECTis, however, a good method to treat late stage cancer patients who are inoperable andnot responsive to radio- and/or chemotherapy.Typical casesMr. Wang, a 52 year-locater, R.N. 09803, complained ofchestpain and distress, andbloody spots in sputum in January 1988. Chest X-ray film revealed a big shadow, 9.5 x11 cm, in the upper lobe of the left Jung. Bronchoscopic examination discovered thatthe mass obstructed the bronchus of the Jeft upper lobe. Squamous cell carcinomawas diagnosed by pathological examination. (Fig. 1) He could not be operated due tohis cor pulmonale. He received ECT in March 1988. 8 electrodes (4 anodes and ~1cathodes) were inserted transcutaneously. Voltage given was 8 V, Current 95 mA, andelectric quantity 1000 coulomb. (Fig. 2) After ECT, chest pain and bloody sputumdisappeared. Tumour reduced in size markedly when he was discharged. Six months www.BudwigCenter.com 8
  9. 9. later, the tumour disappeared totally. Hi lived well and resumed his work afterfollowing up for 5 years. (Fig. 3)Mr. Cheng, a 45 year-old staff officer, R.N. 890016, complained of left chest pain anddistress, and cough in September 1992. Chest X-ray film revealed a shadow, 7.5 x 8.0cm, in the left lower lobe and a shadow, 1.2 x 1.3 cm, in the right upper lobe. (Fig. 4)Undifferentiated carcinoma was diagnosed by pathological examination. In October1992, 6 electrodes (2 anodes and 4 cathodes) were inserted into the mass in the leftlower lobe. Voltage given was 7.8 V, current 88 am, and electric quantity 800 coulomb.(Fig. 5) The tumour disappeared after ECT. Traditional medicines and FT 207 weregiven to the patient for 3 months. Tumour in the right upper lobe disappeared also.Two years later, he was found to be well without recurrence. (Fig. 6)Table 1 Diameter (cm) of 386 cases with Jung cancers Table 1 Diameter (cm) of 386 cases with Jung cancers no of 4.0-6.0 6.1-8.0 8.1-10.0 >10 cases n % n % n % n % squamous cell carcinoma 203 47 23.2 86 42.3 47 23.2 23 11.3 adenocarcinoma 138 34 24.6 63 45.7 28 20.3 13 9.4 undifferentiated carcinoma 45 1 2.2 4 8.9 27 60.0 13 28.9 total 386 82 21.3 153 39.6 102 26.4 49 12.7 Table 2 TNM stage of 386 cases with lung cancer no of II IIIa IIIb IV % cases n n% n% n squamous cell carcinoma 203 65 32.0 46 22.7 58 28.6 34 16.7 adenocarcinoma 138 37 26.8 30 21.7 44 31.9 27 19.6 undifferentiated carcinoma 45 1 2.2 13 28.9 20 44.4 11 24.5 total 386 103 26.7 89 23.1 122 31.6 72 18.6 Table 3 Short term effectiveness of 386 cases no of CR PR NC PD CR + PR cases n% n% n% n% nsquamous cell www.BudwigCenter.com 9
  10. 10. carcinoma 203 65 32.0 104 51.3 23 11.2 11 5.4 169 83.3adenocarcinoma 138 32 23.2 56 40.6 23 16.7 27 19.5 88 63.8undifferentiatedcarcinoma 45 2 4.4 19 42.2 13 28.9 11 24.5 21 46.7total 386 99 25.6 179 46.4 59 15.3 49 12.7 278 72,0 Table 5 Size of tumor and effectivenessDiameter no of CR PR NC PD CR n n n + PR (cm) cases % % n% % n 4.0 - 6.0 82 27 32.9 44 53.6 8 9.8 3 3.7 71 86.6 6.1 - 8.0 I53 50 32.7 75 49.0 I8 11.8 10 6.5 125 8I.7 8.1 - 10.0 I02 22 2I.6 42 41.2 20 19.6 I8 17.6 64 62.7 >10.1 49 - - I8 36.7 13 26.6 18 36.7 18 36.7 total 386 99 25.6 179 46.4 59 15.3 49 I2.7 278 72.0 Table 6 One to five year survival rates of 386 cases no ofI 2 3 4 5 % % % % casesn n n n nsquamous cellcarcinoma 203 I83 90.I 163 80.3 130 64.0 91 44.8 72 35.5adenocarcinoma I38 I20 87.0 I03 74.6 81 58.7 52 37.7 38 27.5undifferentiatedcarcinoma 45 30 66.7 29 64.4 16 35.6 I1 24.4 4 - 8.9total 386 333 86.3 295 76.4 227 58.8 154 39.9 1I4 29.5 Table 7 Staging of cancers and 1-5 year survival rates no of I 2 3 . 4Stage n % % n5 cases % n n % n II I03 95 92.2 89 86.4 8I 78.6 49 47.6 46 44.7 IIIa 89 79 88.8 7I 79.8 6I 68.5 42 47.2 36 40.4 IIIb I22 I05 86.I 9I 74.6 67 54.9 54 44.3 32 26.2 IV 72 54 75.0 47 65.3 I8 25:0 9 12.5 - -total 386 333 86.3 298 77.2 227 58.8 I54 39.9 1I4 29.5 www.BudwigCenter.com 10
  11. 11. www.BudwigCenter.com 11

×